000009646 001__ 9646
000009646 005__ 20240124114327.0
000009646 0247_ $$2DOI$$a10.6083/4j03d0427
000009646 037__ $$aETD
000009646 245__ $$aDetection and validation of aberrant splicing in cancer
000009646 260__ $$bOregon Health and Science University
000009646 269__ $$a2022
000009646 336__ $$aDissertation
000009646 502__ $$bPh.D.
000009646 520__ $$aCancers are among the most deadly and intractable of human diseases, for which the standard of care may involve aggressive yet only partially effective therapies. Immunotherapy, which harnesses the body's immune system to target cancer cells and can lead to long-term remission in some of the most advanced treatment-refractory cases, and liquid biopsy assays, which can potentially detect cancer at an earlier and more easily treatable stage, require the identification of cancer-specific genetic variants. Overall in this work, I show the potential scale of sample counts and types required for a comprehensive normal background of splicing against which truly cancer-specific RNA splicing can be identified; the instability of such identifications and their sensitivity to specific methods and filtering parameter values used; and the poor reliability of intron retention detection from short-read RNA-seq data.
000009646 542__ $$fIn copyright - single owner
000009646 650__ $$aImmunotherapy$$020724
000009646 650__ $$aRNA Splicing$$025539
000009646 650__ $$aStandard of Care$$039491
000009646 650__ $$aLiquid Biopsy$$012229
000009646 650__ $$aAlternative Splicing$$029939
000009646 6531_ $$aneoplasm rna
000009646 691__ $$aSchool of Medicine$$041369
000009646 692__ $$aDepartment of Biomedical Engineering$$041397
000009646 7001_ $$aDavid, Julianne K.
000009646 8564_ $$98502b104-b794-4451-bf5c-2e21da9003ae$$s41587449$$uhttps://digitalcollections.ohsu.edu/record/9646/files/David.Julianne.2022.pdf
000009646 905__ $$a/rest/prod/4j/03/d0/42/4j03d0427
000009646 909CO $$ooai:digitalcollections.ohsu.edu:9646$$pstudent-work
000009646 980__ $$aTheses and Dissertations